750
Participants
Start Date
May 12, 2008
Primary Completion Date
September 6, 2011
Study Completion Date
January 10, 2013
cetuximab
cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
brivanib alaninate
brivanib (BMS-582664) 800 mg po, QD
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA - Abbotsford Centre, Abbotsford
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Fraser Valley Cancer Centre, Surrey
BCCA - Vancouver Cancer Centre, Vancouver
CancerCare Manitoba, Winnipeg
The Moncton Hospital, Moncton
The Vitalite Health Network - Dr. Leon Richard, Moncton
Atlantic Health Sciences Corporation, Saint John
Dr. H. Bliss Murphy Cancer Centre, St. John's
The Royal Victoria Hospital, Barrie
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
Grand River Regional Cancer Centre, Kitchener
London Regional Cancer Program, London
Stronach Regional Health Centre at Southlake, Newmarket
Lakeridge Health Oshawa, Oshawa
Ottawa Health Research Institute - General Division, Ottawa
Algoma District Cancer Program, Sault Ste. Marie
Niagara Health System, St. Catharines
Thunder Bay Regional Health Science Centre, Thunder Bay
Toronto East General Hospital, Toronto
Odette Cancer Centre, Toronto
St. Michael's Hospital, Toronto
Univ. Health Network-Princess Margaret Hospital, Toronto
PEI Cancer Treatment Centre,Queen Elizabeth Hospital, Charlottetown
Hopital Charles LeMoyne, Greenfield Park
L'Hotel-Dieu de Levis, Lévis
CHUM - Hopital Notre-Dame, Montreal
McGill University - Dept. Oncology, Montreal
Hopital du Sacre-Coeur de Montreal, Montreal
CHUQ-Pavillon Hotel-Dieu de Quebec, Québec
CHA-Hopital Du St-Sacrement, Québec
Centre hospitalier universitaire de Sherbrooke, Sherbrooke
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Lead Sponsor
NCIC Clinical Trials Group
NETWORK